Last updated 2026-07-26
Total raised
—
Last: Undisclosed Round 2025-03
Stage
Seed
Founded
2008
Headcount
82
HQ
Rehovot, Israel
Sector
Health Tech & Life Sciences
About
Biolojic Design is a biotechnology company that leverages AI and computational biology to design and develop a pipeline of revolutionary therapeutics. The company focuses on creating "smart antibodies" or "multibodies" that can precisely target predefined epitopes and execute novel biological programs, offering enhanced functionality and precision. Their pipeline primarily addresses autoimmune diseases and oncology, aiming to unlock the full potential of well-studied pathways where traditional drugs may have failed. Biolojic's platform has generated the first AI-designed antibody to enter clinical trials, which is now in phase 2 clinical trials.
Headcount over time
82 employees (2026-09) · 1 point
Offices
Rehovot, Israel · HQ / main office
Show all offices (1 more)
- Boston, United States
Q&A
- What is Biolojic Design's primary focus?
- Biolojic Design uses AI and computational design to transform antibodies into intelligent, programmable medicines for autoimmune diseases and oncology.
- Which company did Biolojic Design partner with for drug discovery in June 2024?
- In June 2024, Biolojic Design landed a drug discovery collaboration with Merck, potentially worth up to 346 million euros.
- What was a significant collaboration for Biolojic Design in December 2023?
- In December 2023, Teva acquired rights for Biolojic Design's asthma treatment.
- What was a key development for Biolojic Design in April 2022?
- In April 2022, the first-ever computationally designed antibody created by Biolojic Design entered human clinical trials in cancer patients.
- Who was appointed as Chief Scientific Officer for Biolojic Design in September 2022?
- In September 2022, Biolojic Design appointed Ronald Herbst, Ph.D., as Chief Scientific Officer.
- What was the nature of Biolojic Design's collaboration with Nektar Therapeutics in February 2021?
- In February 2021, Biolojic Design entered a research collaboration and license option agreement with Nektar Therapeutics to develop computationally designed antibodies against a novel target for the potential treatment of autoimmune disease.
- What was the collaboration between Lilly and Biolojic Design in March 2021?
- In March 2021, Lilly and Biolojic Design announced a research collaboration to discover and develop antibody therapies for diabetes.
Team · 15
Yanay Ofran
Founder · Founder & CEO
Micah Pearlman
Chief Operating Officer
Ronald Herbst
Chief Scientific Officer
Roger Waltzman
Chief Medical Officer
Inbar Amit
SVP, Research & Preclinical Development
Hezi Sasson
SVP, Research & Tech Development
Neal Curran
Chief Business Officer
Eugene Bauer
Senior Advisor
Michael Hayden
Senior Advisor
Nils Lonberg
Senior Advisor
Mace Rothenberg
Senior Advisor
Alan S. Roemer
Senior Advisor
John Hastewell
Senior Advisor
Tim Garnett
Senior Advisor
Michael Kalos
Senior Advisor
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentDigital HealthcareMedical Decision Support
Technologies
BiologicalsMoleculesArtificial IntelligenceMachine Learning
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business model
B2B
Highlights
1 PatentsVerified
Tags
bioconvergencetherapeuticsbioinformaticsdecision-supportnanotechnologyroboticsdigital-healthcaredrug-discoveryimmunologyhealthcarecancer-therapyantibodiesartificial-intelligencepharma-companies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | biolojic.com |
|---|---|
| linkedin.com/company/18152425 | |
| X / Twitter | twitter.com/BiolojicDesign |
| facebook.com/BiolojicDesign | |
| Wikipedia | he.wikipedia.org/wiki/%D7%91%D7%99%D7%95%D7%9C%D7%95%D7%92'% |
| Wikidata | wikidata.org/wiki/Q138603508 |
Identifiers & details
| Founded | 2008 |
|---|---|
| Employees (exact) | 82 |
| Offices | Boston |
| Wikidata QID | Q138603508 |
Radar intelligence
Patents
| EPO | 7 |
|---|
Web history (Wayback)
| Domain | biolojic.com |
|---|
Wikidata
| QID | Q138603508 |
|---|
Certificate / subdomain footprint
| Subdomains | 7 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514201391 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2008-11-10 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 1 — shares_capital (1) |
| Registered address | רמון אילן 6 נס ציונה |
Recent registry events
| Date | Event |
|---|---|
| 2025-11-20 | העברת מניות |